A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform



Status:Active, not recruiting
Conditions:Schizophrenia, Psychiatric, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 35
Updated:3/13/2019
Start Date:July 8, 2015
End Date:October 26, 2019

Use our guide to learn which trials are right for you!

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

The purpose of the study is to compare effectiveness of paliperidone palmitate (PP:
paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP
[that is oral paliperidone extended release {ER}, oral risperidone, or another OAP]) in
delaying time to treatment failure. The study will also evaluate changes in cognition,
functioning, brain intracortical myelin (ICM) volume following treatment with PP compared
with OAP in participants with recent-onset schizophrenia or schizophreniform disorder.

A Prospective, matched-control, Randomized (assignment of study drug by chance), open-label,
flexible-dose, study in participants with recent-onset schizophrenia or schizophreniform
disorder to compare disease progression and disease modification following treatment with PP
long-acting injection (once-monthly followed by 3-month injections) or OAP (Any of the
following 7 OAPs are permitted: aripiprazole, haloperidol, olanzapine, paliperidone ER,
perphenazine, quetiapine, and risperidone). The study consists of 3 parts. Part-1 (Oral
Run-In Phase), Part-2 (Disease Progression) and Part-3 (Extended Disease Progression and
Disease Modification) with unique endpoints. Screening period will be up to 4 Weeks. Duration
of Parts will be as: 2 months for Part-1, 9 months for Part-2 and Part-3. All participants
will initially receive oral paliperidone ER or oral risperidone in Part-1. After
paliperidone/risperidone treatment in Part-1, participants will be randomized into 1:2 ratio
to receive PP or OAP in Part-2. Participants who complete Part-2 will enter into Part-3
wherein OAP group participants of Part-2 will be re-randomized into 1:1 ratio to OAP-OAP
group and OAP-PP group, and PP group will continue without further randomization. Treatment
failures will be evaluated in Part-2 and Part-3 of the study. Also changes in cognition,
functioning, brain intracortical myelin (ICM) volume will be evaluated in the study.
Participants' safety will be monitored throughout.

Inclusion Criteria:

- Participant must have a current diagnosis of schizophrenia (295.90) or
schizophreniform disorder (295.40) as defined by Diagnostic and Statistical Manual of
Mental Disorders, 5th edition (DSM-5) and confirmed by the Structured Clinical
Interview for DSM-5 Disorders (SCID) with a first psychotic episode within the last 24
months prior to the screening visit

- Participant requires treatment with an antipsychotic medication

- Participant must sign an informed consent form (ICF) indicating that he or she
understands the purpose of and procedures required for the study and are willing to
participate in the study

- Participant must have available a designated individual (example, family member,
significant other, friend) who has knowledge of the participant and is generally aware
of the participants daily activities, and who agrees to let the study site personnel
know of changes in the participants circumstances when the participant is not able to
provide this information. The designated individual must sign an informed consent form

- Participant is anticipated to have a stable place of residence for the duration of the
trial

Exclusion Criteria:

- Participant has a current DSM-5 diagnosis of dissociative disorder, bipolar disorder,
major depressive disorder, schizoaffective disorder, autistic disorder, or
intellectual disabilities

- Participant meets the DSM-5 definition of moderate or severe substance use disorder
(except for nicotine) within 2 months prior to Screening

- Participant has a history of neuroleptic malignant syndrome

- Participant has received long-acting injectable (LAI) medication within 2 injection
cycles prior to the Screening visit

- Participant has mental retardation, defined as pre-morbid intelligence quotient (IQ)
as measured by Wechsler Test of Adult Reading at Screening less than (<) 70
We found this trial at
35
sites
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bothell, WA
Click here to add this to my saved trials
?
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
?
mi
from
Eugene, OR
Click here to add this to my saved trials
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
?
mi
from
Granite City, IL
Click here to add this to my saved trials
Hoffman Estates, Illinois 60194
?
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Itapira,
Click here to add this to my saved trials
Lauderdale Lakes, Florida 33313
?
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
?
mi
from
Leesburg, FL
Click here to add this to my saved trials
?
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Muskegon, MI
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
San Rafael, CA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
?
mi
from
Worcester, MA
Click here to add this to my saved trials